Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
CANTON, Mass., Nov. 11, 2016 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in November:
- The Jefferies London Healthcare Conference on Thursday, November 17th at 12:40 p.m. GMT at the Waldorf Hilton London Hotel
- The 28th Annual Piper Jaffray Healthcare Conference on Wednesday, November 30th at 12:00 p.m. EST at the Lotte New York Palace Hotel
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. For Important Safety Information including full prescribing information visit: http://www.xtampzaer.com/.
Contact: Douglas Carlson Vice President, Corporate Development [email protected]
